Merck's Change To Profit Guidance Provides An Opportunity

JHVEPhotoMerck (NYSE:MRK) has been a strong performer within the Pharma space over the last several years, but is down this summer, following earnings and full-year profit guidance cut. Despite this, Merck remains one of the stronger performers among large healthcare equities, and is likely to return to all-time highs within the next several quarters, and potentially within 2024. There are multiple reasons for the reduced profit guidance, including the slowing growth seen by versions Gardasil, its Human ...